Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Corvus Pharmaceuticals (CRVS) EPS (Basic) (2022 - 2025)

Corvus Pharmaceuticals (CRVS) has 4 years of EPS (Basic) data on record, last reported at -$0.14 in Q3 2025.

  • For Q3 2025, EPS (Basic) rose 76.67% year-over-year to -$0.14; the TTM value through Sep 2025 reached -$0.64, up 30.43%, while the annual FY2023 figure was -$0.56, 37.08% up from the prior year.
  • EPS (Basic) reached -$0.14 in Q3 2025 per CRVS's latest filing, down from -$0.11 in the prior quarter.
  • Across five years, EPS (Basic) topped out at $0.21 in Q1 2025 and bottomed at -$0.6 in Q3 2024.
  • Average EPS (Basic) over 4 years is -$0.16, with a median of -$0.14 recorded in 2023.
  • Peak YoY movement for EPS (Basic): tumbled 400.0% in 2024, then surged 275.0% in 2025.
  • A 4-year view of EPS (Basic) shows it stood at -$0.21 in 2022, then surged by 38.1% to -$0.13 in 2023, then plummeted by 361.54% to -$0.6 in 2024, then soared by 76.67% to -$0.14 in 2025.
  • Per Business Quant database, its latest 3 readings for EPS (Basic) were -$0.14 in Q3 2025, -$0.11 in Q2 2025, and $0.21 in Q1 2025.